

LOOKING FORWARD

Your **TECVAYLI** doctor discussion guide

Let's talk **TECVAYLI** in combination with **DARZALEX FASPRO**® (daratumumab and hyaluronidase-fihj).

 **TECVAYLI**®
(teclistamab-cqyv) Injection for subcutaneous
10 mg/mL and 90 mg/mL

Actor portrayal.

TECVAYLI can be used in combination with **DARZALEX FASPRO** as early as **SECOND-LINE** therapy in patients with relapsed or refractory multiple myeloma who have received at least 1 treatment regimen, including a proteasome inhibitor and an immunomodulatory agent

What is **TECVAYLI**® (teclistamab-cqyv)?

TECVAYLI is a prescription medicine used to treat adults with multiple myeloma that has come back or did not respond to prior treatment:

- in combination with daratumumab and hyaluronidase-fihj in people who have already received at least 1 treatment regimen, including a proteasome inhibitor and an immunomodulatory agent.
- alone in people who have received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

It is not known if **TECVAYLI** is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about **TECVAYLI**?

TECVAYLI can cause side effects that are serious, life-threatening or cause death, including cytokine release syndrome (CRS) and neurologic problems.

- **Cytokine Release Syndrome (CRS).** Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:
 - fever (100.4 °F or higher)
 - difficulty breathing
 - chills
 - dizziness or lightheadedness
 - fast heartbeat
 - feeling anxious
 - confusion or restlessness
 - headache
 - increased liver enzymes in your blood. See “**What are the possible side effects of **TECVAYLI**?**” for information about the signs and symptoms of liver problems.

Due to the risk of CRS, you will receive **TECVAYLI** on a “step-up dosing” schedule. You should be hospitalized for 48 hours after the first and second step-up doses and should stay close to a healthcare facility and be monitored by a healthcare provider for 48 hours after you receive your first treatment dose.

- During the step-up dosing schedule your **TECVAYLI** dose will be increased for the first 3 doses. You will receive:
 - a smaller step-up dose as your first dose on day 1 of treatment
 - an increased step-up dose as your second dose, usually around day 3 or 4 of treatment
 - an increased dose as your first treatment dose, usually around day 7 of treatment

Please read additional Important Safety Information throughout and accompanying full Prescribing Information, including **Boxed WARNING**, for **TECVAYLI**.

Tips for having a discussion with **your doctor about TECVAYLI**



Talk about what’s important to you

Bring up the topics that are most important to you at the start of your visit so your doctor clearly understands your priorities.



Come with your questions ready

Make a list of what you want to ask so that if you are pressed for time, you can share the list directly with your doctor. You’ll see some sample questions provided on the following pages.



Bring a family member or friend

Taking notes, helping you remember, thinking of new questions, and providing support are just a few of the tasks a family member or friend may be able to help with.



Use the Notes pages


On the next pages of this brochure, write down any questions or topics you may want to discuss with your doctor.

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI? (cont’d)

- Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI and how many treatments you will receive.
- If your dose of TECVAYLI is delayed for any reason, you may need to repeat the step-up dosing schedule.
- Before each step-up dose and your first treatment dose of TECVAYLI you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines with future doses.
- **Neurologic problems.** Tell your healthcare provider or get medical help right away if you develop any signs and symptoms of neurologic problems, including:
 - headache
 - jerking movements
 - rigid muscles
 - feeling restless
 - numbness and tingling (feeling like “pins and needles”)
 - feeling less alert
 - feeling disorientated, confused, or seeing or hearing things that are not real (hallucinations)
 - trouble speaking
 - muscle spasms
 - tremor
 - double vision
 - changes in your handwriting
 - problems walking
 - muscle weakness in your body or face
 - burning, throbbing, or stabbing pain
 - feeling sleepy
 - memory problems

Please read additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.



“ To the doctors and nurses who are always ready to listen ”

Actor portrayal.

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with TECVAYLI and treat you as needed. Your healthcare provider may temporarily stop or completely stop your treatment with TECVAYLI if you develop CRS or neurologic problems.

• **TECVAYLI is available only through the TECVAYLI and TALVEY® Risk Evaluation and Mitigation Strategy (REMS) due to the risk of CRS and neurologic problems.**

You will receive a Patient Wallet Card from your healthcare provider. **Carry the Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The Patient Wallet Card lists signs and symptoms of CRS and neurologic problems.

Get medical help right away if you develop any of the signs and symptoms listed on the Patient Wallet Card. You may need to be treated in a hospital.

If you have any questions about TECVAYLI, ask your healthcare provider.

See “What are the possible side effects of TECVAYLI?” for more information about side effects.



Questions to get the conversation going



Here are some questions to consider asking your doctor about TECVAYLI (teclistamab-cqyv) in combination with DARZALEX *FASPRO* (daratumumab and hyaluronidase-fihj). You may have other questions not listed here.

#1 Considering TECVAYLI in combination with DARZALEX *FASPRO*

- ☐ Is this combination right for me at this time, and why?
- ☐ Could this combination be a good option for me in the future?
- ☐ How are bispecific antibodies like TECVAYLI different from other multiple myeloma treatment options?
- ☐ Could any of my prior treatments affect how this combination could work for me?
- ☐ How does this combination work in my body?
- ☐ Could this combination interact with any other treatments I am on?

Write down any additional questions and thoughts you may have here.

Notes:

IMPORTANT SAFETY INFORMATION (cont’d)

What is the most important information I should know about TECVAYLI? (cont’d)

Before you receive TECVAYLI, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- are pregnant or plan to become pregnant. TECVAYLI may harm your unborn baby.
 - Your healthcare provider should do a pregnancy test before you start treatment with TECVAYLI.
 - You should use effective birth control (contraception) during treatment and for 5 months after your last dose of TECVAYLI.
 - Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with TECVAYLI.

Please read additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.

Notes:

- are breastfeeding or plan to breastfeed. It is not known if TECVAYLI passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of TECVAYLI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive TECVAYLI?

- TECVAYLI will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach-area (abdomen), your thigh or another area of your body may be injected.
- See “What is the most important information I should know” at the beginning of this Important Safety Information for information about how you will receive TECVAYLI.
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with TECVAYLI.

Questions to get the conversation going (cont'd)



#2 Starting TECVAYLI (teclistamab-cqyv) in combination with DARZALEX *FASPRO* (daratumumab and hyaluronidase-fihj)

- ☐ How will I receive this combination?
- ☐ When starting this combination, will both medications be administered at the same time?
- ☐ How often is this combination administered after I finish my TECVAYLI step-up dosing schedule?
- ☐ Will I need to use any steroids when I start this combination?
- ☐ Where will I receive my step-up doses of TECVAYLI?
- ☐ What should I do if I miss a dose?

Write down any additional questions and thoughts you may have here.

Notes:

IMPORTANT SAFETY INFORMATION (cont'd)

What should I avoid while receiving TECVAYLI?

Do not drive or operate heavy or dangerous machinery during and for 48 hours after your TECVAYLI step-up dosing schedule is completed, or at any time during treatment with TECVAYLI if you develop new neurologic symptoms such as dizziness, confusion, tremors, sleepiness, or any other symptoms that impair your consciousness, until the symptoms go away. See **“What is the most important information I should know about TECVAYLI?”** for more information about signs and symptoms of neurologic problems.

Please read additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.

Notes:

What are the possible side effects of TECVAYLI?

TECVAYLI can cause serious side effects, including:

- See “What is the most important information I should know about TECVAYLI?”
- **Liver problems.** TECVAYLI can cause liver problems that may cause death. Increases in liver enzymes can happen with or without CRS. **Tell your healthcare provider if you develop any symptoms of a liver problem including:**
 - tiredness
 - loss of appetite
 - pain in your right upper stomach area (abdomen)
 - dark urine
 - yellowing of your skin or white part of your eyes
- **Infections.** TECVAYLI can cause bacterial and viral infections that are severe, life-threatening, or that may cause death.
 - Your healthcare provider may prescribe medicines to help prevent infections and treat you as needed if you develop an infection during treatment with TECVAYLI.
 - Tell your healthcare provider right away if you get a fever, chills or any signs or symptoms of an infection.

Questions to get the conversation going (cont'd)



#3 Results with **TECVAYLI** (teclistamab-cqyv) in combination with **DARZALEX FASPRO** (daratumumab and hyaluronidase-fihj)

- How would I know if this combination is working?
- What are the potential benefits of this combination?
- What do the different types of responses (such as complete response, partial response, stringent complete response, and very good partial response) mean, and how does that relate to how I may respond?

Write down any additional questions and thoughts you may have here.

Notes:

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of **TECVAYLI**? (cont'd)

- Decreased white blood cell counts.** Fever sometimes also happens with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will treat you as needed.
- Allergic reactions and injection site reactions.**
 - Allergic reactions:** can include fever, rash, swollen tongue, or trouble breathing. **Get medical help right away if you develop any symptoms of an allergic reaction during treatment with **TECVAYLI**.**
 - Injection site reactions:** can include redness, heat, swelling, bruising, bacterial skin infection (cellulitis), discomfort, blood collection under the skin at the injection site (hematoma), and rash. Tell your healthcare provider if you develop any severe injection site reactions.

Please read additional Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING, for **TECVAYLI**.

Notes:

Your healthcare provider will check your liver enzymes and white blood cell counts before you start and during your treatment with **TECVAYLI**.

Your healthcare provider will monitor you for signs and symptoms of these serious side effects during treatment and may temporarily or permanently stop **TECVAYLI** if you develop severe side effects.

The most common side effects of **TECVAYLI** when used alone include:

- | | | |
|--------------------------------|-------------------------------------|-------------|
| • fever | • tiredness | • headache |
| • CRS | • upper respiratory tract infection | • pneumonia |
| • muscle, joint, and bone pain | • nausea | • diarrhea |
| • injection site reaction | | |

Questions to get the conversation going (cont'd)



#4 Side effects with TECVAYLI (teclistamab-cqyv) in combination with DARZALEX FASPRO (daratumumab and hyaluronidase-fihj)

- What are the possible side effects of this combination?
- Would I have to stop taking this combination if I experience side effects?
- Could I experience more severe side effects as I will be getting a combination of two therapies?
- What should I do if I think I may be experiencing a side effect?
- What is the most important information I should tell my care team?
- Is there anything I could do to reduce the risk of infections?

Write down any additional questions and thoughts you may have here.

Notes:

IMPORTANT SAFETY INFORMATION (cont'd)

What are the possible side effects of TECVAYLI? (cont'd)

The most common side effects of TECVAYLI when used with daratumumab and hyaluronidase-fihj include:

- | | | |
|--|---|--|
| <ul style="list-style-type: none"> • low blood levels of antibodies called immunoglobulins • upper respiratory tract infection • CRS • cough • diarrhea | <ul style="list-style-type: none"> • muscle, joint, and bone pain • COVID-19 • pneumonia • injection site reaction • tiredness | <ul style="list-style-type: none"> • fever • headache • nausea • stomach area pain or cramps • decreased weight |
|--|---|--|

Notes:

The most common severe abnormal blood test results with TECVAYLI include: decreased white blood cells, red blood cells, and platelets.

These are not all the possible side effects of TECVAYLI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.

cp-324738v8

What is TECVAYLI® (teclistamab-cqyv)?

TECVAYLI is a prescription medicine used to treat adults with multiple myeloma that has come back or did not respond to prior treatment:

- in combination with daratumumab and hyaluronidase-fihj in people who have already received at least 1 treatment regimen, including a proteasome inhibitor and an immunomodulatory agent.
- alone in people who have received at least 4 treatment regimens, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

It is not known if TECVAYLI is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about TECVAYLI?

TECVAYLI can cause side effects that are serious, life-threatening or cause death, including cytokine release syndrome (CRS) and neurologic problems.

- **Cytokine Release Syndrome (CRS).** Tell your healthcare provider or get medical help right away if you develop any signs or symptoms of CRS, including:
 - fever (100.4 °F or higher)
 - difficulty breathing
 - chills
 - dizziness or lightheadedness
 - fast heartbeat
 - feeling anxious
 - confusion or restlessness
 - headache
 - increased liver enzymes in your blood. See “What are the possible side effects of TECVAYLI?” for information about the signs and symptoms of liver problems.

Due to the risk of CRS, you will receive TECVAYLI on a “step-up dosing” schedule. You should be hospitalized for 48 hours after the first and second step-up doses and should stay close to a healthcare facility and be monitored by a healthcare provider for 48 hours after you receive your first treatment dose.

- During the step-up dosing schedule your TECVAYLI dose will be increased for the first 3 doses. You will receive:
 - a smaller step-up dose as your first dose on day 1 of treatment
 - an increased step-up dose as your second dose, usually around day 3 or 4 of treatment
 - an increased dose as your first treatment dose, usually around day 7 of treatment
- Your healthcare provider will decide the number of days to wait between your doses of TECVAYLI and how many treatments you will receive.
- If your dose of TECVAYLI is delayed for any reason, you may need to repeat the step-up dosing schedule.
- Before each step-up dose and your first treatment dose of TECVAYLI you will receive medicines to help reduce your risk of CRS. Your healthcare provider will decide if you need to receive medicines with future doses.

- **Neurologic problems.** Tell your healthcare provider or get medical help right away if you develop any signs and symptoms of neurologic problems, including:
 - headache
 - jerking movements
 - rigid muscles
 - feeling restless
 - numbness and tingling (feeling like “pins and needles”)
 - feeling less alert
 - feeling disorientated, confused, or seeing or hearing things that are not real (hallucinations)
 - trouble speaking
 - muscle spasms
 - tremor
 - double vision
 - changes in your handwriting
 - problems walking
 - muscle weakness in your body or face
 - burning, throbbing, or stabbing pain
 - feeling sleepy
 - memory problems

Your healthcare provider will monitor you for signs and symptoms of CRS and neurologic problems during treatment with TECVAYLI and treat you as needed. Your healthcare provider may temporarily stop or completely stop your treatment with TECVAYLI if you develop CRS or neurologic problems.

- **TECVAYLI is available only through the TECVAYLI and TALVEY® Risk Evaluation and Mitigation Strategy (REMS) due to the risk of CRS and neurologic problems.** You will receive a Patient Wallet Card from your healthcare provider. **Carry the Patient Wallet Card with you at all times and show it to all of your healthcare providers.** The Patient Wallet Card lists signs and symptoms of CRS and neurologic problems. **Get medical help right away if you develop any of the signs and symptoms listed on the Patient Wallet Card.** You may need to be treated in a hospital.

If you have any questions about TECVAYLI, ask your healthcare provider.

See “What are the possible side effects of TECVAYLI?” for more information about side effects.

Before you receive TECVAYLI, tell your healthcare provider about all of your medical conditions, including if you:

- have an infection
- are pregnant or plan to become pregnant. TECVAYLI may harm your unborn baby.
 - Your healthcare provider should do a pregnancy test before you start treatment with TECVAYLI.
- You should use effective birth control (contraception) during treatment and for 5 months after your last dose of TECVAYLI.
- Tell your healthcare provider right away if you become pregnant or think that you may be pregnant during treatment with TECVAYLI.
- are breastfeeding or plan to breastfeed. It is not known if TECVAYLI passes into your breast milk. Do not breastfeed during treatment and for 5 months after your last dose of TECVAYLI.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive TECVAYLI?

- TECVAYLI will be given to you by your healthcare provider as an injection under your skin (subcutaneous injection), usually in your stomach-area (abdomen), your thigh or another area of your body may be injected.
- **See “What is the most important information I should know” at the beginning of this Important Safety Information for information about how you will receive TECVAYLI.**
- If you miss any appointments, call your healthcare provider as soon as possible to reschedule your appointment. It is important for you to be monitored closely for side effects during treatment with TECVAYLI.

What should I avoid while receiving TECVAYLI?

Do not drive or operate heavy or dangerous machinery during and for 48 hours after your TECVAYLI step-up dosing schedule is completed, or at any time during treatment with TECVAYLI if you develop new neurologic symptoms such as dizziness, confusion, tremors, sleepiness, or any other symptoms that impair your consciousness, until the symptoms go away. See “What is the most important information I should know about TECVAYLI?” for more information about signs and symptoms of neurologic problems.

What are the possible side effects of TECVAYLI? TECVAYLI can cause serious side effects, including:

- See “What is the most important information I should know about TECVAYLI?”
- **Liver problems.** TECVAYLI can cause liver problems that may cause death. Increases in liver enzymes can happen with or without CRS. **Tell your healthcare provider if you develop any symptoms of a liver problem including:**
 - tiredness
 - loss of appetite
 - pain in your right upper stomach area (abdomen)
 - dark urine
 - yellowing of your skin or white part of your eyes
- **Infections.** TECVAYLI can cause bacterial and viral infections that are severe, life-threatening, or that may cause death.
 - Your healthcare provider may prescribe medicines to help prevent infections and treat you as needed if you develop an infection during treatment with TECVAYLI.
 - Tell your healthcare provider right away if you get a fever, chills or any signs or symptoms of an infection.
- **Decreased white blood cell counts.** Fever sometimes also happens with low white blood cell counts and may be a sign that you have an infection. Your healthcare provider will treat you as needed.

- **Allergic reactions and injection site reactions.**
 - **Allergic reactions:** can include fever, rash, swollen tongue, or trouble breathing. **Get medical help right away if you develop any symptoms of an allergic reaction during treatment with TECVAYLI.**
 - **Injection site reactions:** can include redness, heat, swelling, bruising, bacterial skin infection (cellulitis), discomfort, blood collection under the skin at the injection site (hematoma), and rash. Tell your healthcare provider if you develop any severe injection site reactions.

Your healthcare provider will check your liver enzymes and white blood cell counts before you start and during your treatment with TECVAYLI.

Your healthcare provider will monitor you for signs and symptoms of these serious side effects during treatment and may temporarily or permanently stop TECVAYLI if you develop severe side effects.

The most common side effects of TECVAYLI when used alone include:

- fever
- CRS
- muscle, joint, and bone pain
- injection site reaction
- tiredness
- upper respiratory tract infection
- nausea
- headache
- pneumonia
- diarrhea

The most common side effects of TECVAYLI when used with daratumumab and hyaluronidase-fihj include:

- low blood levels of antibodies called immunoglobulins
- upper respiratory tract infection
- CRS
- cough
- diarrhea
- muscle, joint, and bone pain
- COVID-19
- pneumonia
- injection site reaction
- tiredness
- fever
- headache
- nausea
- stomach area pain or cramps
- decreased weight

The most common severe abnormal blood test results with TECVAYLI include: decreased white blood cells, red blood cells, and platelets.

These are not all the possible side effects of TECVAYLI.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please read accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.

cp-324738v8




Ask your doctor about TECVAYLI

If you are considering or currently receiving TECVAYLI in combination with DARZALEX *FASPRO* (daratumumab and hyaluronidase-fihj), you may have some questions. This guide can help get a conversation started with your doctor and help get those questions answered.

Learn more about

TECVAYLI in combination with
DARZALEX *Faspro*

Scan the QR code* with your smartphone, and tap the link to learn more about TECVAYLI.



*Data rates may apply.

Please read Important Safety Information throughout and accompanying full Prescribing Information, including Boxed WARNING, for TECVAYLI.

© Johnson & Johnson and its affiliates 2026 04/26 cp-571520v1

Johnson & Johnson

 **TECVAYLI**[®]
(teclistamab-cqyv) Injection for
subcutaneous use
10 mg/mL and 90 mg/mL